TY - JOUR
T1 - Therapeutic Drug Monitoring of Posaconazole
T2 - an Update
AU - Dekkers, Bart
AU - Bakker, Martijn
AU - van der Elst, Kim
AU - Sturkenboom, Marieke
AU - Veringa, Anette
AU - Span, LFR
AU - Alffenaar, Jan-Willem
PY - 2016/6
Y1 - 2016/6
N2 - Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.
AB - Posaconazole is a second-generation triazole agent with a potent and broad antifungal activity. In addition to the oral suspension, a delayed-release tablet and intravenous formulation with improved pharmacokinetic properties have been introduced recently. Due to the large interindividual and intraindividual variation in bioavailability and drug-drug interactions, therapeutic drug monitoring (TDM) is advised to ensure adequate exposure and improve clinical response for posaconazole. Here, we highlight and discuss the most recent findings on pharmacokinetics and pharmacodynamics of posaconazole in the setting of prophylaxis and treatment of fungal infections and refer to the challenges associated with TDM of posaconazole.
U2 - 10.1007/s12281-016-0255-4
DO - 10.1007/s12281-016-0255-4
M3 - Article
SN - 1936-3761
VL - 10
SP - 51
EP - 61
JO - Current Fungal Infection Reports
JF - Current Fungal Infection Reports
IS - 2
ER -